Miller Edward (CIK 0001619252)

Latest company ownership

KLRS - Kalaris Therapeutics, Inc.
Role: General Counsel
Shares held
346,348
Last filed at
Dec 11, 2024
Confidence Score
50.1
2025Q4
Confidence Score History
2021Q1 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Feb 21, 2025 Feb 24, 2025 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -106 -0.49% ✗ $1.1K
Jan 23, 2025 Jan 27, 2025 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -52 -0.24% ✗ $494
Jan 10, 2025 Jan 13, 2025 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -409 -0.08% ✗ $180
Nov 19, 2024 Nov 20, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -432 -0.09% ✗ $237
Nov 5, 2024 Nov 6, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -2,272 -0.45% ✗ $2K
Oct 21, 2024 Oct 23, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -1,401 -0.28% ✗ $1.1K
Oct 3, 2024 Oct 4, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -377 -0.07% ✗ $307.2
Aug 19, 2024 Aug 20, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -422 -0.08% ✗ $320.5
Aug 5, 2024 Aug 7, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -2,323 -0.46% ✗ $1.7K
Jul 19, 2024 Jul 23, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -1,391 -0.27% ✗ $1K
Jul 2, 2024 Jul 3, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -379 -0.07% ✗ $272.9
May 17, 2024 May 21, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -420 -0.08% ✗ $314.7
May 3, 2024 May 7, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -2,311 -0.45% ✗ $1.8K
Apr 19, 2024 Apr 23, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -1,383 -0.27% ✗ $1K
Apr 2, 2024 Apr 4, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -368 -0.07% ✗ $284.1
Feb 20, 2024 Feb 22, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -385 -0.07% ✗ $267.7
Feb 5, 2024 Feb 6, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 47.5 -8,869 -1.70% ✗ $5.9K
Jan 23, 2024 Jan 25, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -1,302 -0.25% ✗ $873.4
Jan 4, 2024 Jan 8, 2024 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -424 -0.08% ✗ $270.9
Dec 2, 2022 Jan 23, 2023 Kalaris Therapeutics, Inc. General Counsel Sell 51.3 -2,573 -0.58% ✓ $13.1K
Nov 14, 2022 Nov 16, 2022 Kalaris Therapeutics, Inc. General Counsel Sell 51.3 -2,358 -0.53% ✓ $21K
Oct 20, 2022 Oct 26, 2022 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -553 -0.22% ✗ $5.2K
Oct 19, 2022 Oct 24, 2022 Kalaris Therapeutics, Inc. General Counsel Sell 52.5 -553 -0.12% ✗ $5.2K
Mar 1, 2021 Mar 3, 2021 Kalaris Therapeutics, Inc. General Counsel Sell 45.0 -6,000 -1.53% ✓ $232.7K